Compare ADMA Biologics Inc (ADMA) vs Campbell Soup Co. (CPB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Campbell Soup Co. — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Campbell Soup Co. trades at $22.22 (market cap $6.83B). The key difference: Campbell Soup Co. is far larger — about 3.2× ADMA Biologics Inc's market cap, and Campbell Soup Co. pays a 6.81% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | CPB | |
|---|---|---|
Market Cap | $2.13B | $6.83B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $34.03 |
52-Week Low | $7.60 | $20.00 |
Enterprise Value | $2.20B | $13.44B |
Dividend Yield | — | 6.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Campbell's (CPB) trades at $22.90, down 1.8% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The stock offers a 7% dividend yield but faces margin pressures with net income margin at 6.12%. Recent Q1 2026 earnings beat expectations at $0.50 EPS, though sales declined 4% year-over-year. The company is implementing cost cuts and portfolio simplification while expanding through partnerships like the new gluten-free soup with Banza.
CPB presents a value opportunity with low P/E of 11.11 and P/S of 0.68, but faces structural challenges including margin deterioration and competitive pressures. Analyst consensus leans cautious with 55% hold ratings and $19.75 price target below current levels. The high dividend yield provides income support, but investors should monitor execution of cost-saving initiatives and consumer response to new product innovations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →
